Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate

BJU International

Volumn 113, Issue SUPPL. 2, 2014, Pages 69-72

  Losco, Giovanni ^a   Studd, Rod ^a   Blackmore, Timothy ^a  

^a WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Antibiotic prophylaxis; Biopsy; Carbapenems; Prostatic neoplasms; Sepsis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; ERTAPENEM; IMMUNOSUPPRESSIVE AGENT; ANTIINFECTIVE AGENT; BETA LACTAM; CARBAPENEM DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; INFECTION PREVENTION; INFECTION RISK; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; RISK FACTOR; SEPSIS; TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY; TRAVEL; URINARY TRACT INFECTION; AGED; ANTIBIOTIC PROPHYLAXIS; BIOPSY; DRUG COMBINATION; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ESCHERICHIA COLI INFECTION; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PROSTATE TUMOR; QUESTIONNAIRE; RECTUM; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIBIOTIC PROPHYLAXIS; BIOPSY; CARBAPENEMS; PROSTATIC NEOPLASMS; SEPSIS;

AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BETA-LACTAMS; BIOPSY; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RECTUM; RISK ASSESSMENT; RISK FACTORS; SEPSIS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84905387448     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12590     Document Type: Article

References (26)

1. Challacombe B, Dasgupta P, Patel U et al. Recognizing and managing the complications of prostate biopsy. BJU Int 2011; 108: 1233
2. Nam RK, Saskin R, Lee Y et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183: 963-8
3. Loeb S, van den Heuvel S, Zhu X et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 1110-4
4. Loeb S, Carter HB, Berndt S et al. Complications of prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830
5. Loeb S, Van den Heurel S, Chu Z et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 1110
6. Sanders A, Buchan N. Infection-related hospital admission after transrectal biopsy of the prostate. Aust NZ J Surg 2013; 83: 246-8
7. Puig J, Darnell A, Bermúdez P et al. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary? Eur Radiol 2006; 16: 939-43
8. Kapoor DA, Klimberg IW, Malek GH et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998; 52: 552-8
9. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85: 682-5
10. Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011; 78: 511-4
11. Ismail M, Saini A, Nigam R. Ciprofloxacin-resistant infection after transrectal ultrasonography-guided prostate biopsy: should we reassess our practice? BJU Int 2011; 108: 305-6
12. Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011; 77: 1035-41
13. Akduman B, Akduman D, Tokgöz H et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology 2011; 78: 250-5
14. Liss MA, Chang A, Santos R et al. Prevalence and significance of fluoroquinolone resistant Eschericia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 2011; 185: 1283-8
15. Kehinde EO, Al-Maghrebi M, Sheikh M, Anim JT. Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. J Urol 2013; 189: 911-5
16. Adibi M, Hornberger B, Bhat D, Raj G, Roehrborn CG, Lotan Y. Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 2013; 189: 535-40
17. Batura D, Rao GG, Nielson PB, Charlett A. Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 2011; 107: 760-4
18. Simsir A, Kismali E, Mammadov R, Gunaydin G, Cal C. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int 2010; 84: 395-9
19. Williamson DA, Roberts SA, Paterson DL et al. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 2012; 54: 1406-12
20. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study 1998-2007. J Antimicrob Chemother 2009; 64: 169-74
21. Peralta G, Sánchez MB, Garrido JC et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Anticrob Chemother 2007; 60: 855-63
22. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 2008; 14: 1041-7
23. Feliciano J, Teper E, Ferrandino M et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis? J Urol 2008; 179: 952-5
24. Nys S, Okeke IN, Kariuki S, Dinant GJ, Driessen C, Stobberingh EE. Antibiotic resistance of faecal Escherichia coli from healthy volunteers from eight developing countries. J Antimicrob Chemother 2004; 54: 952-5
25. Batura D, Rao GG, Nielsen PB. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 2010; 106: 1017-20
26. Duplessis CA, Bavaro M, Simons MP et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012; 79: 556-61